CSL, AU000000CSL8

CSL stock cut to Neutral as Evans and Partners lowers target

Published on 11/18/2026 at 09:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
CSL stock faces a Neutral call from Evans and Partners after a target cut. The next earnings release is listed for February 10, 2027.

Analyst view and next date

  • Evans and Partners moved its CSL recommendation to Neutral on November 16.
  • The company's next earnings release is listed for February 10, 2027.
CSL, AU000000CSL8, Illustration mit AI erstellt.

On November 16, Evans and Partners cut its recommendation on CSL to Neutral and lowered its price target to AUD 197.24, according to a MarketScreener report citing MT Newswires. The report was published on November 16 at 8:18 p.m. Eastern time.

The move places a more cautious analyst view alongside CSL's planned management transition and its recovery agenda. MarketScreener identifies CSL's main businesses as CSL Behring, CSL Seqirus and CSL Vifor, covering plasma products, vaccines, iron deficiency and nephrology therapies.

Next results remain ahead

MarketScreener lists CSL's next earnings release for February 10, 2027, identified as the company's second-quarter fiscal 2027 release. That date is the next scheduled reporting point shown with the analyst update.

CSL stock traded at 121.11 euros on Lang & Schwarz at 09:18 CET on Wednesday, November 18.

CSL Limited stock facts

  • Company: CSL Limited
  • ISIN: AU000000CSL8
  • Lang & Schwarz quote: 121.11 euros at 09:18 CET on November 18, 2026
  • Analyst action: Evans and Partners moved the recommendation to Neutral
  • Price target: AUD 197.24

The Euro Stoxx 50 provides a broader regional equity-market context for investors.

More news and analyses on CSL stock

Disclaimer...
en | AU000000CSL8 | CSL | boerse | 70530178 | bgmi